Drugs that contain Alcaftadine
1. Lastacaft patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5468743 | ABBVIE | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
Apr, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(2 years from now) | |
| US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of LASTACAFT before it's drug patent expiration?
More Information on Dosage
LASTACAFT family patents
